1stOncology™: Cancer Intelligence Service – Page 817 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Targeted therapy delivered

On June 17, 2025 Lisata therapeutics presented its corporate presentation (Press release, Lisata Therapeutics, JUN 17, 2025, View Source [SID1234653944]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Ashvattha Therapeutics to Present Data on Novel Nanomedicine Radiotracers at SNMMI Annual Meeting

On June 17, 2025 Ashvattha Therapeutics ("Ashvattha"), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target and reprogram activated cells in regions of inflammation, reported it will present data on two novel nanomedicine radiotracers at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, June 21 – 24, 2025 in New Orleans, LA (Press release, Ashvattha Therapeutics, JUN 17, 2025, View Source [SID1234653943]).

The data will demonstrate the ability to tune Ashvattha’s hydroxyl dendrimer platform to achieve selective uptake in neuroinflammation in humans and in tumor-associated macrophages in cancer animal models.

The company will present findings on two novel nanomedicine radiotracers: flurimedrimer, which selectively targets activated microglia in the human brain to support its neurology pipeline, and a second radiotracer designed to selectively target tumor-associated macrophages, potentially advancing precision imaging in oncology.

SNMMI:

Poster Title: Flurimedrimer, a Novel Nanomedicine Radiotracer, Selectively Targeting Activated Microglia in Human Brain
Presentation Date/Time: Sunday, June 22, 2025; 6:30-7:00pm CDT
Session Type: Molecular Targeting Probes POPs
Presenter: Farshad Moradi, MD, Stanford University

Poster Title: A Novel Nanomedicine Radiotracer, Selectively Targeting Tumor Associated Macrophages
Presentation Date/Time: Monday, June 23, 2025; 10:30 AM-11:15am CDT
Session Type: Poster Session
Presenter: Jeff Cleland, PhD, CEO, Ashvattha Therapeutics

Alligator receives positive scientific advice from EMA on Phase 3 trial of mitazalimab

On June 17, 2025 Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developing tumor-directed immunotherapies, reported that the European Medicines Agency (EMA) has provided positive scientific advice supporting the overall design of the planned Phase 3 study of mitazalimab in metastatic pancreatic cancer (Press release, Alligator Bioscience, JUN 17, 2025, View Source [SID1234653942]).

The advice confirms that the proposed Phase 3 study of mitazalimab in combination with mFOLFIRINOX is appropriately designed to support future marketing authorization application. The guidance confirms that the information submitted supports mitazalimab advancement to registrational trials, and Alligator is continuing preparations for trial initiation in line with regulatory input.

This regulatory feedback represents another key milestone in the late-stage development of mitazalimab and complements the recently announced confirmation by the U.S. Food and Drug Administration (FDA) of the Phase 3 dose.

"We are very pleased with EMA’s endorsement of our Phase 3 trial design and mitazalimab’s Phase 3 readiness, confirming its path to regulatory approval in Europe," said Søren Bregenholt, CEO of Alligator Bioscience. "This advice from EMA aligns very well with previous input from FDA thus enabling a single global Phase 3 study leading to mitazalimab’s potential registration as a new treatment for patients with metastatic pancreatic cancer in these major territories."

Immumem Therapeutics Awarded $75,000 Non-Dilutive Grant Support to Advance Cell Therapy Development

On June 16, 2025 Immumem Therapeutics, an emerging biotechnology company focused on developing novel oncology therapeutics, reported it has been awarded a $75,000 non-dilutive grant from ScaleReady’s G-Rex Grant Program (Press release, Immumem Therapeutics, JUN 16, 2025, View Source [SID1234656571]). This funding will support the advancement of Immumem’s innovative manufacturing processes for next-generation cell therapies.

The competitive grant provides Immumem with critical resources to expand its research platform and accelerate development timelines in the cell and gene therapy space. The award package includes access to advanced bioreactor technology, specialized reagents, and expert consulting services designed to enhance the company’s pre-clinical development capabilities.

"This non-dilutive funding represents a significant opportunity to accelerate our cell therapy manufacturing capabilities while preserving shareholder value," stated a spokesperson for Immumem Therapeutics. "The support from ScaleReady’s G-Rex Grant Program will enable us to optimize our production processes and advance our therapeutic pipeline toward key developmental milestones."

The G-Rex Grant Program is specifically designed to foster innovation within the cell and gene therapy sector by providing promising biotechnology companies with the resources needed to overcome manufacturing challenges and accelerate therapeutic development.

Immumem Therapeutics will utilize the grant to further refine its proprietary cell therapy manufacturing platform, with the goal of improving production efficiency and therapeutic potency. This advancement aligns with the company’s mission to develop more effective and accessible treatments for patients with cancer and other serious diseases.

For more information about Immumem Therapeutics and its development programs, please visit www.immumemtx.com or the company’s knowledge center.

Biosceptre presenting our AML Modular CAR-T program at the prestigious European Hematological Congress

On June 16, 2025 Biosceptre reported that lead scientists Alex Joechner and Dr. Cindy Li from the Biosceptre Laboratory were honoured with an invitational oral presentation at the European Hematology Association (EHA) (Free EHA Whitepaper) 2025 Annual Congress, held this week in Milan (Press release, Biosceptre, JUN 16, 2025, View Source;utm_medium=rss&utm_campaign=biosceptre-presenting-our-aml-modular-car-t-program-at-the-prestigious-european-hematological-congress [SID1234654004]).

With more than 14,000 delegates in attendance, EHA (Free EHA Whitepaper) is one of the world’s premier events for hematological research. Of the more than 3,500 abstracts submitted last year, only 235 were selected for oral presentation—highlighting the exceptional quality and impact of the work presented by our team.

The 15-minute oral presentation showcased compelling new data on Biosceptre’s modular CAR-T platform, focusing on its function and therapeutic potential in treating Acute Myeloid Leukemia (AML). This recognition reflects the scientific strength of our BRiDGECAR program and the dedication of our team in advancing next-generation cell therapies for challenging blood cancers.

We congratulate Alex and Dr. Li on this achievement and thank the EHA (Free EHA Whitepaper) for the opportunity to present on the global stage.